Project Grant R44CA291285
Award Date
6/4/25
Completion Date
5/31/27
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...
This $400,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel, RNA interference-based therapeutic to treat prostate cancer by Nuago Therapeutics, Inc. The therapeutic approach involves delivering short interfering RNA (siRNA) molecules derived from CAG trinucleotide repeat sequences, which have been shown to be toxic to cancer cells. This Phase I project will evaluate the uptake and activity of the siRNA-based...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $624,001 to New York University School of Medicine to develop a new class of compounds called multivalent peptoid conjugates (MPCs) that can antagonize the androgen receptor (AR) in prostate cancer cells. The project aims to demonstrate that these novel MPC compounds can stop the growth of prostate cancer cells that have become resistant to standard anti-androgen treatments....
This federal Project Grant award of $571,271 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research team at the University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in...
The National Cancer Institute (NCI) awarded a $1,304,828 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to conduct a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The grant will support specific aims to: 1) evaluate the safety and tolerability of (R)-9B, and 2) assess peripheral blood and tumor...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,811,052 to Manzanita Pharmaceuticals Inc. to complete IND-enabling studies for NERVELIGHT, a novel nerve imaging agent for use during radical prostatectomies. The key products and services being developed under this two-year award include toxicology and safety pharmacology studies in rats and dogs to confirm the safety profile of...